Literature DB >> 19280226

Fatal infection in children with lupus nephritis treated with intravenous cyclophosphamide.

Kamolwish Laoprasopwattana1, Pornsak Dissaneewate, Prayong Vachvanichsanong.   

Abstract

A knowledge of the causes and risk factors of fatal infection in childhood lupus nephritis (LN) patients treated with intravenous cyclophosphamide (IVCY) is important to enable optimal treatment. During an 11-year period (1996-2007), severe infection cases occurred in 31/84 (36.9%) patients with 64 infection episodes in our central referral institution in southern Thailand. Fatal infections occurred in 13/31 (41.9%) patients, most (11/13, 84.6%) during the first infective episode. The major causative organisms of the fatal infections were fungus and Gram-negative bacilli. Fatal infections were more likely to occur in patients with a prior history of treatment with pulse methylprednisolone and in patients with more active LN, as evidenced by the higher proteinuria and serum creatinine levels and lower hemoglobin and lymphocyte counts in this group than in patients with non-fatal infections. Multivariate analysis indicated that factors associated with fatal infection were prior treatment with pulse methylprednisolone [odds ratio (OR) 11.2, 95% confidence interval (CI) 1.9-61.0], renal failure (OR 5.9, 95% CI 1.0-34.8), and fungal infection (OR 23.9, 95% CI 1.9-298.2). Cases of active LN treated with IVCY and pulse methylprednisolone who later develop severe infection that fails to respond to antibiotics should be carefully investigated for fungal infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19280226     DOI: 10.1007/s00467-009-1152-7

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  41 in total

Review 1.  Strongyloides stercoralis hyperinfection in systemic lupus erythematosus and the antiphospholipid syndrome.

Authors:  Claudia S Mora; María I Segami; José A Hidalgo
Journal:  Semin Arthritis Rheum       Date:  2006-09-01       Impact factor: 5.532

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

3.  Causes of death in Korean patients with systemic lupus erythematosus: a single center retrospective study.

Authors:  W U Kim; J K Min; S H Lee; S H Park; C S Cho; H Y Kim
Journal:  Clin Exp Rheumatol       Date:  1999 Sep-Oct       Impact factor: 4.473

4.  Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality.

Authors:  M M Ward; F Donald
Journal:  Arthritis Rheum       Date:  1999-04

5.  Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.

Authors:  Frédéric A Houssiau; Carlos Vasconcelos; David D'Cruz; Gian Domenico Sebastiani; Enrique de Ramon Garrido Ed; Maria Giovanna Danieli; Daniel Abramovicz; Daniel Blockmans; Alessandro Mathieu; Haner Direskeneli; Mauro Galeazzi; Ahmet Gül; Yair Levy; Peter Petera; Rajko Popovic; Radmila Petrovic; Renato Alberto Sinico; Roberto Cattaneo; Josep Font; Geneviève Depresseux; Jean-Pierre Cosyns; Ricard Cervera
Journal:  Arthritis Rheum       Date:  2002-08

Review 6.  Infectious complications in SLE after immunosuppressive therapies.

Authors:  Insoo Kang; Sung Hwan Park
Journal:  Curr Opin Rheumatol       Date:  2003-09       Impact factor: 5.006

7.  Clinical outcome of febrile neutropenia in children with cancer using ceftazidime and aminoglycosides.

Authors:  Kamolwish Laoprasopwattana; Pornpimol Pruekprasert; Vichai Laosombat; Malai Wongchanchailert
Journal:  Pediatr Hematol Oncol       Date:  2007-12       Impact factor: 1.969

Review 8.  Infection and disease activity in systemic lupus erythematosus: a review of hospitalized patients.

Authors:  K N Duffy; C M Duffy; D D Gladman
Journal:  J Rheumatol       Date:  1991-08       Impact factor: 4.666

9.  Systemic lupus erythematosus--survival patterns. Experience with 609 patients.

Authors:  D J Wallace; T Podell; J Weiner; J R Klinenberg; S Forouzesh; E L Dubois
Journal:  JAMA       Date:  1981-03-06       Impact factor: 56.272

10.  Risk of infection in hospitalised children with systemic lupus erythematosus: a 10-year follow-up.

Authors:  Yu-Shu Chen; Yao-Hsu Yang; Yu-Tsai Lin; Bor-Luen Chiang
Journal:  Clin Rheumatol       Date:  2004-04-14       Impact factor: 2.980

View more
  5 in total

1.  Serious Infection Rates Among Children With Systemic Lupus Erythematosus Enrolled in Medicaid.

Authors:  Linda T Hiraki; Candace H Feldman; Francisco M Marty; Wolfgang C Winkelmayer; Hongshu Guan; Karen H Costenbader
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-09-21       Impact factor: 4.794

2.  A case of infantile systemic lupus erythematosus with severe lupus nephritis and EBV infection.

Authors:  Natsuko Kishi; Kenichi Suga; Sato Matsuura; Yukiko Kinoshita; Maki Urushihara; Shuji Kondo; Etsuko Kitano; Michiyo Hatanaka; Hajime Kitamura; Tetsuya Sato; Akihiko Maeda; Shoji Kagami
Journal:  CEN Case Rep       Date:  2013-02-14

Review 3.  Management and outcomes in children with lupus nephritis in the developing countries.

Authors:  Priyanka Khandelwal; Srinivasavaradan Govindarajan; Arvind Bagga
Journal:  Pediatr Nephrol       Date:  2022-10-18       Impact factor: 3.651

Review 4.  Diagnosis and management of infectious complications of childhood rheumatic diseases.

Authors:  Rhina D Castillo; Wendy De la Pena; Katherine A B Marzan
Journal:  Curr Rheumatol Rep       Date:  2013-04       Impact factor: 4.592

5.  Intravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritis.

Authors:  Prayong Vachvanichsanong; Pornsak Dissaneewate; Edward McNeil
Journal:  Int Urol Nephrol       Date:  2012-12-07       Impact factor: 2.370

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.